Aflibercept biosimilar (Amgen)

Amgen announced positive first quarter 2025 financial results, citing strong global demand across its product portfolio and successful new product launches.

Amgen reports strong 2024 performance with $33.4 billion revenue, but faces patent expiration challenges for blockbusters Otezla and Enbrel, driving strategic pivot towards biosimilars and portfolio diversification.

Amgen disclosed during Q4 earnings that the FDA has placed their obesity drug AMG 513 clinical trial on hold, though executives believe the issue is not related to the medication itself.

Regeneron Pharmaceuticals has reported positive Phase III results for Libtayo, its PD-1 inhibitor, showing significant survival benefits for high-risk cutaneous squamous cell carcinoma patients, marking a notable advancement over Merck's Keytruda which failed in this indication.

The FDA has approved Steqeyma (ustekinumab-stba) and Yesintek (ustekinumab-kfce) as biosimilars to Stelara, offering new options for patients with autoimmune and inflammatory conditions.